Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of HRS-3095 tablets in chronic spontaneous urticaria
CTR20262047Phase 2Active
- Sponsor
- Chengdu Shengdi
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HRS-3095 in chronic idiopathic urticaria (CIU), sponsored by Chengdu Shengdi. Started May 2026; status: active.
02
Drugs
HRS-3095
03
Conditions
chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on CTR20262047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262047.